Cruz A A, Popov T, Pawankar R, Annesi-Maesano I, Fokkens W, Kemp J, Ohta K, Price D, Bousquet J
ProAR, Programme for Control of Asthma and Allergic Rhinitis in Bahia, Federal University of Bahia School of Medicine, and CNPq, Salvador, Brazil.
Allergy. 2007;62 Suppl 84:1-41. doi: 10.1111/j.1398-9995.2007.01551.x.
This update aimed to review the new evidence available to support or refute prior Allergic Rhinitis and its Impact on Asthma (ARIA) statements. A Medline search of publications between 2000 and 2005 was conducted, with articles selected by experts. New evidence supports previous ARIA statements, such as: (i) allergic rhinitis (AR) is a risk factor for asthma; (ii) patients with persistent rhinitis should be evaluated for asthma; (iii) most patients with asthma have rhinitis; (iv) a combined strategy should be used to treat the airways and (v) in low- to middle-income countries, a different strategy may be needed. The increased risk of asthma has also been found among sufferers from non-AR. Recent reports show AR is a global problem. Many studies demonstrated parallel increasing prevalence of asthma and rhinitis, but in regions of highest prevalence, it may be reaching a plateau. Factors associated with a reduced risk of asthma and AR have been identified, confirming previous findings of protection related to exposure to infections. Treatment of rhinitis with intranasal glucocorticosteroids, antihistamines, leukotriene antagonists or immunotherapy may reduce morbidity because of asthma. To take advantage of the paradigm of unified airways, there is a need to rationalize diagnosis and treatment to optimize management.
本次更新旨在回顾现有新证据,以支持或反驳先前的变应性鼻炎及其对哮喘的影响(ARIA)声明。检索了2000年至2005年间发表在Medline上的文献,并由专家挑选文章。新证据支持先前的ARIA声明,例如:(i)变应性鼻炎(AR)是哮喘的危险因素;(ii)应评估持续性鼻炎患者是否患有哮喘;(iii)大多数哮喘患者患有鼻炎;(iv)应采用联合策略治疗气道;以及(v)在低收入和中等收入国家,可能需要采用不同的策略。在非AR患者中也发现哮喘风险增加。最近的报告显示AR是一个全球性问题。许多研究表明哮喘和鼻炎的患病率同时上升,但在患病率最高的地区,可能已趋于平稳。已确定与哮喘和AR风险降低相关的因素,证实了先前关于感染暴露具有保护作用的研究结果。使用鼻用糖皮质激素、抗组胺药、白三烯拮抗剂或免疫疗法治疗鼻炎可能会降低哮喘的发病率。为了利用统一气道的模式,有必要使诊断和治疗合理化,以优化管理。